Vitamin D, Eczema and LL-37: What Skin Trials Found

Your daughter’s eczema flares every winter, and a parent group is sure the fix is vitamin D. One post goes further: vitamin D switches on LL-37, the skin’s own germ-fighting peptide, and the same LL-37 is sold online as a research peptide. Is any of that backed by studies in people with eczema?

Partly. Vitamin D can raise cathelicidin, the protein LL-37 is cut from, in eczema skin, but the trials disagree, and the largest placebo-controlled pediatric trial measuring LL-37 found no change in the peptide and no change in eczema severity. A winter trial in Mongolia, where vitamin D is often low, did find modest improvement.

People with atopic dermatitis, the most common type of eczema, get more skin infections, including with Staphylococcus aureus. Lab work in the 2000s found that eczema skin makes less of some natural antimicrobial peptides, and that the gene for cathelicidin responds to the active form of vitamin D. That raised a simple idea: give vitamin D by mouth and see whether eczema skin makes more of its own defense peptide.

The biopsy studies split

The first test, published as a short report in 2008 by researchers at the University of California, San Diego, gave oral vitamin D3 for three weeks to 14 people with eczema and 14 without. In skin taken from eczema patches, cathelicidin gene activity rose from a median of about 3.5 to about 23.9 on the study’s relative scale. The study had no placebo group.

A placebo-controlled follow-up led by the same UC San Diego researcher randomized 30 people with eczema, 30 without and 16 with psoriasis to vitamin D3 or placebo for 21 days. Blood vitamin D went up, but skin cathelicidin, another defense peptide, an allergy-linked signal and eczema scores did not change significantly. The authors suggested season and location may matter, since vitamin D levels shift through the year.

In Chile, 22 children with moderate to severe eczema took weekly oral vitamin D3 for six weeks with no comparison group. Their blood levels roughly doubled, cathelicidin rose in tape-strip samples from the skin, and severity scores improved. A randomized trial from the same team then assigned 101 children to weekly vitamin D3 or placebo for six weeks. Severity scores fell almost equally in both groups, and there were no differences in LL-37 or in staph on eczema patches.

What the eczema trials show overall

The clearest positive result did not measure LL-37 at all. In Ulaanbaatar, 107 children whose eczema worsened each winter were randomized to vitamin D3 or placebo for one month, alongside moisturizer and skin-care teaching for everyone. Eczema scores improved more with vitamin D, by about 6.5 points versus 3.3. A 2024 meta-analysis of 11 randomized trials with 686 people found a small to moderate overall benefit, with results varying between trials, and called for larger, longer studies.

So the peptide story is a plausible mechanism, not a proven explanation. The studies measured the body’s own cathelicidin after vitamin D, not any LL-37 product. Research-catalog LL-37 sold for laboratory use was not tested in any of these trials and has no eczema evidence behind it.

What to do with this

MedlinePlus lists the standard tools: medicines, skin creams, light therapy and good skin care, plus avoiding irritating soaps, fabrics and known triggers. If winter flares are a pattern, it is reasonable to ask the pediatrician whether a vitamin D level check makes sense, especially for children with little sun exposure or darker skin. The NIH Office of Dietary Supplements warns that very high vitamin D intake can cause nausea, kidney stones and worse, so amounts belong with a clinician. Not medical advice.

Can Vitamin D Help Eczema by Raising the Skin Peptide LL-37?

The biopsy studies split

What the eczema trials show overall

What to do with this

Sources

Related reading

Share this:

Like this: